CarrerasLeaders Call

The CarrerasLeaders Call is Open: a new Postdoctoral Program to empower Future Leaders to Fight Blood Cancers

The aim of the CarrerasLeaders program is to fund 16 excellent postdoctoral researchers for a period of 3 years. The selected participants will join the Josep Carreras Institute’s research groups or research-performing Scientific Platforms and perform international secondments to academic and non-academic institutions. The program receives funding from the European Commission Horizon Europe Marie Sklodowska Curie Actions (MSCA) COFUND Program and counts with the collaboration of the Josep Carreras International Foundation and the scientific coordination of Dr Buschbeck.

Read more
10x Genomics Certificate

The Josep Carreras Leukaemia Research Institute, first center accredited in Visum Spatial Transciptomics by 10x Genomics

The Single Cell unit of the Josep Carreras Leukaemia Research Institute has received the seal of quality that accredits the institution as a reference center in Spain for the Visum Spatial Gene Expression technology, from the company 10x Genomics. The accreditation, has been formalized at the first 10x Genomics Spatial Symposium, organized jointly and which has taken place in the main building of the Josep Carreras Institute, at the Can Ruti campus in Badalona.

Read more
AECC Acte Entrega Ajuts 2022

Three researchers from the Josep Carreras Institute receive grants from the AECC to promote research against leukemia

Last Monday, March 13, the Spanish Association Against Cancer (AECC) held an awards ceremony at their Barcelona headquarters for their 2022 research grants. Two researchers from the Josep Carreras Leukaemia Research Institute, Dr. Jeanine Diesch and Dr. Talia Velasco, received grants addressed to researchers. In addition, Dr. Marcus Buschbeck received funding for a general fundamental research project.

Read more
Premi Manel Esteller 1

The Sant Boi City Council and the Josep Carreras Institute create the "Manel Esteller Award for Initiation in Biomedical Research"

The Sant Boi City Council, in collaboration with the Josep Carreras Leukaemia Research Institute, has created the "Manel Esteller Award for Initiation in Biomedical Research" to promote biomedical research on leukemia, lymphomas and other malignant blood diseases. The award was officially presented at the Sant Joan de Déu Campus Docent in Sant Boi on Friday, March 10, in a ceremony attended by the researcher, the Minister of Science and Innovation, Diana Morant, and the mayor of the city, Lluïsa Moret.

Read more

The European Commission supports a promising CAR-T therapy against leukemia developed at the Josep Carreras Institute

A consortium led by OneChain Immunotherapeutics, spin-off of the Josep Carreras Leukaemia Research Institute, has received the support of the European Commission to bring an innovative CAR-T therapy to the bedside. The novelty of the treatment lies in the fact that it does not depend on extraction of the patient's own cells, and it simultaneously attacks two cancer cell targets.

Read more
Mar Mallo & Francesc Solé

New molecular features associated worst prognosis myelodysplastic syndromes with normal karyotype

In a recent publication at the journal eJHaem, a team of researchers from the Josep Carreras Leukaemia Research Institute have given supporting evidence that the presence of the so-called “regions of homozygosity” in the genome of patients with myelodysplastic syndrome with no detectable chromosomic abnormalities confer a worst prognosis, especially when these regions are larger than 25 megabases.

Read more
M. Esteller, A. Bueno, L. Ciudad, C. García-Prieto

A study by the Cancer Epigenetics group selected among the best articles in leukemia

The high-impact journal Leukemia recognizes a study of the Cancer Epigenetics Group, led by Dr Manel Esteller at the Josep Carreras Leukaemia Research Institute, among the “Readers Choice: The best of Leukemia 2022”. The research describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the epigenetic modifications of a type of its genetic material: the messenger RNA.

Read more

Recent publications

Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP, Caballero Berrocal JC, Sala C, Maggioni G, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, D'Amico S, Tentori CA, Ubezio M, Campagna A, Russo A, Mannina D, Lanino L, Chiusolo P, Giaccone L, Voso MT, Riva M, Oliva EN, Zampini M, Riva E, Nibourel O, Bicchieri M, Bolli N, Rambaldi A, Passamonti F, Savevski V, Santoro A, Germing U, Kordasti S, Santini V, Diez-Campelo M, Sanz G, Sole F, Kern W, Platzbecker U, Ades L, Fenaux P, Haferlach T, Castellani G, Della Porta MG

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Journal of Clinical Oncology 17 Mar 2023, JCO2201784. Epub 17 Mar 2023
Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M.
More information
Noguera-Castells A, García-Prieto CA, Álvarez-Errico D, Esteller M

Validation of the new EPIC DNA methylation microarray (900K EPIC v2) for high-throughput profiling of the human DNA methylome.

Epigenetics 5 Mar 2023, 18 (1) 2185742.
DNA methylation, one of the best characterized epigenetic marks in the human genome, plays a pivotal role in gene transcription regulation and other biological processes in humans. On top of that, the DNA methylome undergoes profound changes in cancer and other disorders. However, large-scale and population-based studies are limited by high costs and the need for considerable expertise in data analysis for whole-genome bisulphite-sequencing methodologies. Following the success of the EPIC DNA methylation microarray, the newly developed Infinium HumanMethylationEPIC version 2.0 (900K EPIC v2) is now available. This new array contains more than 900,000 CpG probes covering the human genome and excluding masked probes from the previous version. The 900K EPIC v2 microarray adds more than 200,000 probes covering extra DNA cis-regulatory regions such as enhancers, super-enhancers and CTCF binding regions. Herein, we have technically and biologically validated the new methylation array to show its high reproducibility and consistency among technical replicates and with DNA extracted from FFPE tissue. In addition, we have hybridized primary normal and tumoural tissues and cancer cell lines from different sources and tested the robustness of the 900K EPIC v2 microarray when analysing the different DNA methylation profiles. The validation highlights the improvements offered by the new array and demonstrates the versatility of this updated tool for characterizing the DNA methylome in human health and disease.
More information
O. Calvete, J. Mestre, A. Jerez, F. Solé, None

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw

Cancers 26 Feb 2023, . Epub 26 Feb 2023
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. However, since these risk factors are not exclusive for secondary MDSs and there are multiple overlapping scenarios, a comprehensive and definitive classification is yet to come. In addition, a sporadic MDS might arise after a primary tumor fulfills the diagnostic criteria of MDS-pCT without a causative cytotoxicity. In this review, we describe the triggering pieces of a secondary MDS jigsaw: previous cytotoxic therapy, germline predisposition and clonal hematopoiesis. Epidemiological and translational efforts are needed to put these pieces together and ascertain the real weight of each of these pieces in each MDS patient. Future classifications must contribute to understanding the role of secondary MDS jigsaw pieces in different concomitant or independent clinical scenarios associated with the primary tumor.
Caillot M, Miloudi H, Taly A, Profitós-Pelejà N, Santos JC, Ribeiro ML, Maitre E, Saule S, Roué G, Jardin F, Sola B

Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin lymphoma.

Molecular Oncology 2 Feb 2023, . Epub 2 Feb 2023
Exportin 1 (XPO1) is the main nuclear export receptor that controls the subcellular trafficking and the functions of major regulatory proteins. XPO1 is overexpressed in various cancers and small inhibitors of nuclear export (SINEs) have been developed to inhibit XPO1. In primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL), the XPO1 gene may be mutated on one nucleotide and encodes the mutant XPO1
More information
Calvete O, Mestre J, Durmaz A, Gurnari C, Maciejewski JP, Solé F

Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?

British Journal of Haematology 30 Jan 2023, . Epub 30 Jan 2023More information